Kathleen A Cooney

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9015420/publications.pdf

Version: 2024-02-01

157 papers	14,992 citations	41344 49 h-index	19190 118 g-index
162 all docs	162 docs citations	162 times ranked	19277 citing authors

#	Article	IF	Citations
1	Association of germline rare pathogenic mutations in guidelineâ€recommended genes with prostate cancer progression: A metaâ€analysis. Prostate, 2022, 82, 107-119.	2.3	4
2	The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. British Journal of Cancer, 2022, 126, 791-796.	6.4	13
3	KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	3
4	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology, 2021, 79, 353-361.	1.9	28
5	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. European Urology, 2021, 79, 419-426.	1.9	36
6	â€œSheroesâ€• Celebrating Women in Medicine Month During the Time of COVID-19. Academic Medicine, 2021, 96, e17-e18.	1.6	0
7	Germline mutations in DNA damage repair genes and HOXB13 among African American men diagnosed with early-onset prostate cancer.. Journal of Clinical Oncology, 2021, 39, 10505-10505.	1.6	0
8	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	1.9	21
9	Observed evidence for guidelineâ€recommended genes in predicting prostate cancer risk from a large populationâ€based cohort. Prostate, 2021, 81, 1002-1008.	2.3	10
10	Prostate Cancer Predisposition. Urologic Clinics of North America, 2021, 48, 283-296.	1.8	12
11	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
12	Provider Practice Competition and Adoption of Medicareâ€™s Oncology Care Model. Medical Care, 2020, 58, 154-160.	2.4	5
13	Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. British Journal of Cancer, 2020, 123, 1356-1359.	6.4	11
14	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
15	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	1.6	170
16	Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precision Oncology, 2020, 4, 139-151.	3.0	7
17	Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. Journal of Clinical Oncology, 2020, 38, 1807-1813.	1.6	27
18	Factors associated with appropriate and low-value PSA testing. Cancer Epidemiology, 2020, 66, 101724.	1.9	2

#	Article	IF	Citations
19	What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 2020, 80, 441-450.	2.3	8
20	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	5.4	41
21	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 332-339.e2.	1.9	5
22	Relative risks of prostate cancer associated with different family cancer histories.. Journal of Clinical Oncology, 2019, 37, 1505-1505.	1.6	0
23	Mitochondrial alterations may underlie race-specific differences in cancer risk and outcome. Journal of Clinical Investigation, 2019, 129, 2187-2188.	8.2	6
24	A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate, 2018, 78, 607-615.	2.3	57
25	Rare germline mutations in African American men diagnosed with earlyâ€onset prostate cancer. Prostate, 2018, 78, 321-326.	2.3	20
26	Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 2018, 78, 186-192.	2.3	11
27	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
28	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	1.6	169
29	Broadening the View of Germline Mutations in Kidney Cancer. JAMA Oncology, 2018, 4, 1235.	7.1	0
30	Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes. European Urology, 2018, 74, 720-721.	1.9	1
31	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	2.3	12
32	Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiology, 2018, 56, 112-117.	1.9	9
33	Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center. Journal of Cancer Education, 2017, 32, 871-877.	1.3	6
34	gsSKAT: Rapid gene set analysis and multiple testing correction for rareâ€variant association studies using weighted linear kernels. Genetic Epidemiology, 2017, 41, 297-308.	1.3	9
35	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	1.9	256
36	Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer, 2017, 123, 3925-3932.	4.1	45

#	Article	IF	Citations
37	Editorial Comment. Journal of Urology, 2017, 197, 66-66.	0.4	0
38	Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Transactions of the American Clinical and Climatological Association, 2017, 128, 14-23.	0.5	11
39	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Caseâ€Control Sequencing Studies. Genetic Epidemiology, 2016, 40, 461-469.	1.3	5
40	Advances in inherited cancers: Introduction. Seminars in Oncology, 2016, 43, 527.	2.2	1
41	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. American Journal of Human Genetics, 2016, 99, 877-885.	6.2	1,555
42	HOXB13 mutations and prostate cancer risk. BJU International, 2016, 118, 496-497.	2.5	2
43	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	3.8	37
44	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Advances in Radiation Oncology, 2016, 1, 59-66.	1.2	6
45	Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 766-772.	2.5	3
46	Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. European Urology, 2016, 70, 209-210.	1.9	11
47	Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics, 2016, 17, 231-240.	1.3	59
48	HOXB13 and other high penetrant genes for prostate cancer. Asian Journal of Andrology, 2016, 18, 530.	1.6	13
49	Abstract B40: Rare variant discovery in known cancer genes from whole-exome sequencingof African American hereditary prostate cancer families. , 2016, , .		0
50	Comprehensive serial molecular profiling of an â€œN of 1â€•exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. Journal of Hematology and Oncology, 2015, 8, 109.	17.0	22
51	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
52	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human Genetics, 2015, 134, 439-450.	3.8	45
53	The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1366-1372.	2.5	47
54	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Research and Treatment, 2015, 152, 163-172.	2.5	23

#	Article	IF	Citations
55	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. Neoplasia, 2015, 17, 385-399.	5.3	212
56	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
57	Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis. , 2015, , .		0
58	Genome-Wide Association Scan for Variants Associated with Early-Onset Prostate Cancer. PLoS ONE, 2014, 9, e93436.	2.5	25
59	Risk of second primary tumors in men diagnosed with prostate cancer: A populationâ€based cohort study. Cancer, 2014, 120, 2735-2741.	4.1	105
60	HOXB13 G84Eâ€“related Familial Prostate Cancers. American Journal of Surgical Pathology, 2014, 38, 615-626.	3.7	41
61	Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Human Genetics, 2014, 133, 347-356.	3.8	24
62	Prevalence of the <scp>HOXB13</scp>â€…<scp>G84E</scp> prostate cancer risk allele in men treated with radical prostatectomy. BJU International, 2014, 113, 830-835.	2.5	21
63	Statin Use and the Risk of Recurrence After Radical Prostatectomy in a Cohort of Men With Inherited and/or Early-onset Forms of Prostate Cancer. Urology, 2014, 83, 1356-1361.	1.0	13
64	Prostate cancer in young men: an important clinical entity. Nature Reviews Urology, 2014, 11, 317-323.	3.8	206
65	Mutational landscape of candidate genes in familial prostate cancer. Prostate, 2014, 74, 1371-1378.	2.3	16
66	Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate, 2014, 74, 983-990.	2.3	18
67	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 2013, 132, 5-14.	3.8	166
68	Testing for the Recurrent HOXB13 G84E Germline Mutation in Men with Clinical Indications for Prostate Biopsy. Journal of Urology, 2013, 189, 849-853.	0.4	12
69	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
70	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
71	Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, 2013, 1-12.	0.6	180
72	Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. Journal of Clinical Oncology, 2013, 31, 1713-1718.	1.6	144

#	Article	IF	Citations
73	Abstract 2564: Identification of a novel SPOP missense mutation from targeted next-generation sequencing of men with chromosome 17-q linkage.. , 2013, , .		0
74	Prevalence and Correlates of Vitamin and Supplement Usage Among Men With a Family History of Prostate Cancer. Integrative Cancer Therapies, 2012, 11, 83-89.	2.0	14
75	Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Familial Cancer, 2012, 11, 595-600.	1.9	15
76	Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Medical Genetics, 2012, 13, 46.	2.1	5
77	Genetic variation in Glutathione S-Transferase Omega-1, Arsenic Methyltransferase and Methylene-tetrahydrofolate Reductase, arsenic exposure and bladder cancer: a caseâ€“control study. Environmental Health, 2012, 11, 43.	4.0	55
78	Germline Mutations inHOXB13and Prostate-Cancer Risk. New England Journal of Medicine, 2012, 366, 141-149.	27.0	566
79	Early onset prostate cancer has a significant genetic component. Prostate, 2012, 72, 147-156.	2.3	65
80	Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate, 2012, 72, 410-426.	2.3	14
81	Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 2012, 131, 1095-1103.	3.8	21
82	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	2.6	72
83	Abstract 1642: Rare missense variants inMAP3K14andARHGAP27in men with hereditary prostate cancer. , 2012, , .		0
84	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics, 2011, 43, 570-573.	21.4	198
85	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	2.6	49
86	Hereditary prostate cancer as a feature of Lynch Syndrome. Familial Cancer, 2011, 10, 37-42.	1.9	51
87	Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: The flint men's health study. Prostate, 2011, 71, 225-231.	2.3	20
88	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
89	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 23-32.	2.5	88
90	Abstract 5569: The association between statin use and risk of biochemical recurrence in men treated with radical prostatectomy in a cohort of men with inherited forms of prostate cancer. Cancer Research, 2011, 71, 5569-5569.	0.9	3

#	Article	IF	Citations
91	Genomeâ€wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses. Prostate, 2010, 70, 735-744.	2.3	22
92	Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell, 2009, 16, 336-346.	16.8	190
93	Semiparametric Bayesian modeling of random genetic effects in familyâ€based association studies. Statistics in Medicine, 2009, 28, 113-139.	1.6	1
94	Bayesian inference for the stereotype regression model: Application to a caseâ€“control study of prostate cancer. Statistics in Medicine, 2009, 28, 3139-3157.	1.6	18
95	Genomeâ€wide linkage scan for prostate cancer susceptibility from the university of michigan prostate cancer genetics project: Suggestive evidence for linkage at 16q23. Prostate, 2009, 69, 385-391.	2.3	27
96	Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate, 2009, 69, 956-960.	2.3	32
97	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	21.4	389
98	EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Research and Treatment, 2008, 107, 235-242.	2.5	41
99	The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Menâ€™s Health Study. Journal of Human Genetics, 2008, 53, 220-226.	2.3	52
100	Genetic polymorphisms inCYP17,CYP3A4,CYP19A1,SRD5A2,IGF-1, andIGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate, 2008, 68, 296-305.	2.3	60
101	Analysis of the gene coding for the BRCA2â€interacting protein PALB2 in hereditary prostate cancer. Prostate, 2008, 68, 675-678.	2.3	36
102	Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer. International Journal of Cancer, 2008, 122, 2876-2879.	5.1	23
103	Body Composition and Serum Prostate-Specific Antigen: Review and Findings from Flint Menâ€™s Health Study. Urology, 2008, 71, 554-560.	1.0	33
104	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters, 2008, 270, 173-180.	7.2	19
105	Chromosome 17q12 Variants Contribute to Risk of Early-Onset Prostate Cancer. Cancer Research, 2008, 68, 6492-6495.	0.9	40
106	Common Variation in the BRCA1 Gene and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1510-1516.	2.5	37
107	Association between Germline Variation in the FHIT Gene and Prostate Cancer in Caucasians and African Americans. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1294-1297.	2.5	4
108	Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Human Molecular Genetics, 2007, 16, 1271-1278.	2.9	31

#	Article	IF	Citations
109	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. Clinical Genitourinary Cancer, 2007, 5, 318-322.	1.9	8
110	Features of the metabolic syndrome and prostate cancer in Africanâ€American men. Cancer, 2007, 109, 875-881.	4.1	83
111	Sequence variation in Î±â€methylacylâ€CoA racemase and risk of earlyâ€onset and familial prostate cancer. Prostate, 2007, 67, 1507-1513.	2.3	18
112	Multiple regions within 8q24 independently affect risk for prostate cancer. Nature Genetics, 2007, 39, 638-644.	21.4	621
113	Fine-mapping the putative chromosome 17q21â€“22 prostate cancer susceptibility gene to a 10ÂcM region based on linkage analysis. Human Genetics, 2007, 121, 49-55.	3.8	30
114	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 2006, 120, 471-485.	3.8	57
115	Sexual Behavior, Sexually Transmitted Diseases and Prostatitis: The Risk of Prostate Cancer in Black Men. Journal of Urology, 2006, 176, 1108-1113.	0.4	77
116	Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate. Urology, 2006, 67, 423.e5-423.e8.	1.0	20
117	Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology, 2006, 68, 1072-1076.	1.0	13
118	Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate, 2006, 66, 173-179.	2.3	42
119	A common variant associated with prostate cancer in European and African populations. Nature Genetics, 2006, 38, 652-658.	21.4	738
120	Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. Human Genetics, 2006, 118, 716-724.	3.8	16
121	Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Human Genetics, 2006, 119, 400-407.	3.8	21
122	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. Clinical Genitourinary Cancer, 2006, 4, 299-302.	1.9	73
123	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer, 2006, 106, 2617-2623.	4.1	4
124	Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 935-938.	2.5	49
125	APC I1307K and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 468-473.	2.5	8
126	Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14068-14073.	7.1	575

#	Article	IF	Citations
127	Truncating Variants in p53AIP1 Disrupting DNA Damageâ€“Induced Apoptosis Are Associated with Prostate Cancer Risk. Cancer Research, 2006, 66, 10302-10307.	0.9	9
128	Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate, 2005, 64, 60-66.	2.3	4
129	INSPstI polymorphism and prostate cancer in African-American men. Prostate, 2005, 65, 83-87.	2.3	7
130	Identifying Susceptibility Genes for Prostate Cancer--A Family-Based Association Study of Polymorphisms in CYP17, CYP19, CYP11A1, and LH-Â. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2035-2039.	2.5	36
131	Hyperglycemia, Obesity, and Cancer Risks on the Horizon. JAMA - Journal of the American Medical Association, 2005, 293, 235.	7.4	16
132	A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancerâ€“Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics. American Journal of Human Genetics, 2005, 77, 219-229.	6.2	138
133	Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes. Journal of the National Cancer Institute, 2004, 96, 1240-1247.	6.3	72
134	Truncating BRCA1 Mutations Are Uncommon in a Cohort of Hereditary Prostate Cancer Families with Evidence of Linkage to 17q Markers. Clinical Cancer Research, 2004, 10, 5975-5980.	7.0	34
135	Risk perception and concern among brothers of men with prostate carcinoma. Cancer, 2004, 100, 1537-1544.	4.1	34
136	Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology, 2004, 63, 282-287.	1.0	28
137	Association between Agent Orange and prostate cancer: a pilot case-control study. Urology, 2004, 63, 757-760.	1.0	35
138	Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: The Flint Menâ€™s Health Study. Urology, 2004, 64, 959-965.	1.0	16
139	Family history of prostate cancer and relapse after definitive external beam radiation therapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 371-376.	0.8	8
140	R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. Prostate, 2003, 54, 306-309.	2.3	19
141	Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 nearBRCA1. Prostate, 2003, 57, 326-334.	2.3	90
142	Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Menâ€™s Health Study. Urology, 2003, 61, 1086-1091.	1.0	91
143	Prostate cancer early detection practices among men with a family history of disease. Urology, 2003, 62, 470-475.	1.0	15
144	Risk Factors for Lower Urinary Tract Symptoms in a Population-based Sample of African-American Men. American Journal of Epidemiology, 2003, 157, 906-914.	3.4	174

#	Article	IF	Citations
145	Metastatic Dedifferentiated Chordoma With Elevated Î²-hCG. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 274-276.	1.3	7
146	Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology, 2002, 59, 362-367.	1.0	69
147	Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate, 2002, 53, 322-329.	2.3	53
148	Analysis of the Prostate Cancerâ€“Susceptibility Locus HPC20 in 172 Families Affected by Prostate Cancer. American Journal of Human Genetics, 2001, 68, 795-801.	6.2	51
149	Potential selection bias in a community-based study of PSA levels in African-American men. Journal of Clinical Epidemiology, 2001, 54, 142-148.	5.0	26
150	Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology, 2001, 57, 91-96.	1.0	67
151	THE NATURAL HISTORY OF LOWER URINARY TRACT SYMPTOMS IN BLACK AMERICAN MEN: RELATIONSHIPS WITH AGING, PROSTATE SIZE, FLOW RATE AND BOTHERSOMENESS. Journal of Urology, 2001, 165, 1521-1525.	0.4	47
152	THE NATURAL HISTORY OF LOWER URINARY TRACT SYMPTOMS IN BLACK AMERICAN MEN: RELATIONSHIPS WITH AGING, PROSTATE SIZE, FLOW RATE AND BOTHERSOMENESS. Journal of Urology, 2001, , 1521-1525.	0.4	1
153	Tissue Microarray Assessment of Prostate Cancer Tumor Proliferation in African- American and White Men. Journal of the National Cancer Institute, 2000, 92, 937-939.	6.3	68
154	Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology, 1999, 54, 607-611.	1.0	156
155	RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER. Journal of Urology, 1998, 160, 1809-1809.	0.4	10
156	Prostate Cancer Susceptibility Locus on Chromosome 1q: a Confirmatory Study. Journal of the National Cancer Institute, 1997, 89, 955-959.	6.3	193
157	Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genetics, 1995, 9, 439-443.	21.4	380